Although the combination of RY103 and TMZ had no synergistic effect on glioma and was not an ideal treatment strategy for glioma, it was the first trial on the combination of our novel IDO1 inhibitor and a standard therapeutic agent. Here, IDO1 is linked to central nervous system cancer.